Get the Stockscreener App
5.78
3.03%
0.17
Iovance Biotherapeutics Inc stock is traded at $5.78, with a volume of 10.86M.
It is up +3.03% in the last 24 hours and down -1.70% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$5.61
Open:
$5.69
24h Volume:
10.86M
Relative Volume:
1.47
Market Cap:
$1.76B
Revenue:
$32.77M
Net Income/Loss:
$-440.22M
P/E Ratio:
-3.4611
EPS:
-1.67
Net Cash Flow:
$-400.48M
1W Performance:
+3.77%
1M Performance:
-1.70%
6M Performance:
-51.14%
1Y Performance:
-63.35%
1-Day Range:
$5.675
$6.09
1-Week Range:
$5.44
$6.09
52-Week Range:
$5.05
$18.33
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
5.78 | 1.76B | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Iovance Biotherapeutics (IOVA) to Release Quarterly Earnings on Wednesday - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know - Nasdaq
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Iovance Biotherapeutics, Inc. (IOVA) - ACCESS Newswire
My 3 Favorite Stocks to Buy Right Now - The Motley Fool
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) - MSN
Iovance Biotherapeutics to Report Fourth Quarter and Full - GlobeNewswire
Biotech Spotlight: Iovance's Crucial Year-End Results & TIL Therapy Updates Coming Feb 27 - StockTitan
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.3%Time to Buy? - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Banque Pictet & Cie SA - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 1-Year LowShould You Sell? - MarketBeat
Executive Compensation Alert: Iovance's Strategic Move with 305K Share Package for Commercial Chief - StockTitan
Stifel maintains Buy on Iovance Biotherapeutics, target at $21 - MSN
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - AOL
(IOVA) Trading Report - Stock Traders Daily
Iovance Biotherapeutics appoints new chief commercial officer - MSN
Jennison Associates LLC Buys Shares of 66,568 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Lion Biotechnologies Submits Investigational New Drug Application to Conduct Phase 2 Study in Metastatic Melanoma - Marketscreener.com
Iovance Biotherapeutics Shares Fell Today: What's Going On? - Benzinga
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 - br.ADVFN.com
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer - GlobeNewswire
Iovance Lands Former Celgene & BMS Executive to Accelerate TIL Therapy Commercialization | $IOVA - StockTitan
What's Going On With Iovance Biotherapeutics Today? - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 12-Month Low on Analyst Downgrade - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month Low on Analyst Downgrade - MarketBeat
SG Americas Securities LLC Purchases Shares of 69,625 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $7.50 at Piper Sandler - MarketBeat
Oversold Conditions For Iovance Biotherapeutics (IOVA) - Nasdaq
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $23.00 Consensus Target Price from Analysts - MarketBeat
What's Wrong With Iovance Biotherapeutics Stock? - MSN
Institutional owners may consider drastic measures as Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) recent US$122m drop adds to long-term losses - Simply Wall St
(IOVA) Investment Report - Stock Traders Daily
Lion Biotechnologies, Inc. Appoints Michael T. Lotze, MD, as Chief Scientific Officer and Vice President of Research and Development - Marketscreener.com
Stifel maintains Buy on Iovance stock with $21 target - MSN
Where Will Iovance Biotherapeutics Be in 5 Years? - MSN
Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Iovance Biotherapeutics (IOVA) Forecasts Strong Growth Due to Flagship Treatment - TipRanks
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):